Investing

Boundless Bio : BOLD

BOLD

Stock Data

$2.51

$0.06 (2.45%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.

All Boundless Bio Articles

6 Articles

Joshua Rodriguez | Sep 27, 2024 at 1:07 PM EDT

Penny Stocks To Buy With Just $1500: PMVP, BOLD, SPRO

Do you have $1,500 you’d like to use to try investing in penny stocks? Some investments in the category can…

Trey Thoelcke | Apr 7, 2024 at 8:55 AM EDT

Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter

A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as…

Jon C. Ogg | Dec 6, 2019 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon, Sage Therapeutics, Target, Tesla, Trade Desk, Yext and More

Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade…

Chris Lange | Dec 3, 2019 at 12:10 PM EST

Are Audentes Shareholders Getting Enough in the Acquisition?

Audentes Therapeutics shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although…

Jon C. Ogg | Dec 3, 2019 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: Alphabet, Amazon, Beyond Meat, CommScope, Enphase, Nabors, Netflix, Nike, Roku, Tesla, Uber, Williams Companies and More

Tuesday's top analyst upgrades, downgrades and initiations included Alphabet, Amazon.com, Beyond Meat, CommScope, Enphase Energy, Nabors Industries, Netflix, Nike, Roku,…

Chris Lange | Sep 14, 2019 at 7:10 AM EDT

7 Biotechs With Catalysts in the Next Month

Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates…